Cerebral replaces CEO amid federal investigation into prescribing practices


Share post:

Cerebral CEO and cofounder Kyle Robertson is leaving his place on the digital psychological well being firm amid rising controversy over its prescribing practices, notably for managed substances like Adderall.

Dr. David Mou, who has served as Cerebral’s president and chief medical officer, will likely be taking the reins as CEO efficient instantly. He added the president position earlier this month. Along with the CEO shakeup, chief working officer Jessica Muse will now tackle the president job and Thomas Insel, former director of the Nationwide Institute of Psychological Well being and medical advisor for the corporate, will be a part of Cerebral’s board.

The Wall Avenue Journal and Bloomberg reported the board agreed final night time to switch Robertson. In accordance the WSJ, Robertson did not take part within the assembly and misplaced entry to Cerebral’s Slack messaging system with out advance warning. 


Over the previous a number of months, Cerebral has confronted rising scrutiny over its prescribing practices for managed substances. In late April, a former govt sued the corporate, alleging he was fired after elevating affected person security considerations. He mentioned Cerebral aimed to prescribe medicine to all its ADHD sufferers to extend retention. In a press release, the psychological well being firm mentioned it believed these accusations had been “with out benefit.”

Earlier this month, the corporate confirmed it had obtained a grand jury subpoena from the U.S. Lawyer’s Workplace for the Jap District of New York as a part of an investigation into attainable violations of the Managed Substances Act. 

Across the similar time, Cerebral mentioned it will pause the prescription of managed substances to new sufferers. This week, the digital psychological well being firm confirmed it will cease prescribing most managed substances to each new and present sufferers, although it will proceed providing medicine for opioid use dysfunction therapy. 


“We thank Kyle for his service. His imaginative and prescient resulted in what Cerebral is at present: a number one supplier of urgently wanted psychological well being companies to individuals who had been unable or unlikely to acquire therapy,” Mou mentioned in a press release.

“The timing for his thought was fortuitous. When the pandemic struck, Cerebral turned a lifeline for these in want of psychological well being companies. Kyle led the corporate by means of the speedy progress that adopted, serving to lots of of 1000’s of sufferers entry efficient and protected care. As Cerebral enters its subsequent section of progress, we sit up for increasing our companies, guided as at all times by evidence-based medical protocols, to assist those that battle with psychological well being considerations in silence.”

Supply hyperlink


Please enter your comment!
Please enter your name here


Related articles